The National Foundation for Medical Research and Innovation has implemented a strategy focused on supporting gap areas along the innovation pathway for biomedical research.
This targeted support assists researchers to advance their research towards the development of new innovations including medicines, vaccines, diagnostics and devices. These innovations normally require regulatory approval, commercial partnerships and investors as they progress. Learn more.
| Dr. Prashant Bharadwaj |
| Edith Cowan University |
| Alzheimer’s disease |
| Diagnostic |
Key outcomes:
- WA Child Research Foundation, $250,000
- Department of Health WA/FHRIF, $160,000
- Alzheimer’s Research Australia, $300,000
- Channel 7 Telethon grant – childhood dementia, $100,000
| Prof Bernard Flynn |
| Monash University |
| Inflammatory bowel disease |
| Drug |
Key outcomes:
- Term sheet for a VC-backed seed funding start-up company, $2.5m
- Monash Research Innovation Fund, $50,000
- Monash MIPS incubator investment, $50,000
“After being awarded the Dr. John Raftos AM Medal by NFMRI, Prof Flynn applied the $50,000 prize towards research investigating a potential treatment for inflammatory bowel disease. Despite receiving the funding in 2021, substantial progress is already taking place”
| A/Prof Branka Grubor Bauk |
| The University of Adelaide |
| Zika virus |
| Vaccine |
Key achievements to date:
- Industry collaboration with Vaxxas (Australia)
- Industry support from aVaxzipen (UK)
- Industry collaboration with PharmaJet (CO, USA)
- Collaboration with University of Wisconsin – Madison (WI, USA)
A/Prof Grubor-Bauk has developed an innovative, patented and thermally stable Zika virus DNA vaccine that encodes Zika virus non-structural protein 1, NS1. Extensive evaluation of this vaccine in mouse models of Zika infection has shown that it induces strong immunity and confers complete protection against systemic Zika infection. Funding from NFMRI is helping to progress the development a novel Zika virus vaccine by completing pre-clinical evaluation of this Zika virus DNA vaccine enabling Phase I Human Clinical Trials, and generating data for regulatory filing.
| Prof Michael Good AO & Dr Danielle Stanisic |
| Griffith University |
| Malaria |
| Vaccine |
Key outcomes:
- Collaborating with industry and currently in clinical trials
- Signed an agreement with Statens Serum Institute to provide material for the pre-clinical animal studies
- Leveraged over $1m from Rotary Australia to support clinical trial costs of the study
- Clinical trial has received additional funding of $500,000 from Medical Research Future Fund Accelerated Research initiative
- Private trust funding, $570,000
- Private philanthropic donor, $372,027
- Griffith University funding, $334,968
“The funding provided by NFMRI specifically supported the GMP-compliant manufacturing of the vaccine and enabled additional leveraging of funding from Rotary to support the clinical trial activities as well as additional funding from the Medical Research Future Fund Accelerated Research initiative to enable further optimisation and development of a field-deployable vaccine, suitable for malaria endemic areas.”
| A/Prof Peter van Wijngaarden |
| Centre for Eye Research Australia |
| Alzheimer’s disease |
| Device |
Key outcomes:
- Project has leveraged over $5m in additional funding as a result of the grant
- Spin-off company established, Enlighten Imaging
- Well advanced camera prototype has been developed
- Garnered support from the likes of Bill & Melinda Gates and Jeff Bezos via the Alzheimer’s Drug Discovery Foundation
- Awarded NHMRC-EU Joint Programme for Neurodegenerative Disease (JPND) research grant, $1,400,000
- Received support from BioMedTech Horizons MRFF scheme, $1,000,000
“This funding has enabled us to develop and test several prototypes of our retinal camera. This has been instrumental in our ability to secure additional grant funding and accelerated our progress towards the clinic. In addition, Noel Chambers and his team have provided us with invaluable mentorship and access to some of the leading experts in medical research translation who have generously shared their expertise with us. This know-how has been tremendously helpful to us.“
| Prof Bernard Flynn |
| Monash University |
| Pulmonary hypertension |
| Therapeutic |
Key outcomes:
- Established a spin-off company Ankere Therapeutics
- $10,791,639 investment seed funding raised
